adplus-dvertising
Connect with us

Business

Vaccinating young kids may take time but experts ready to discuss parents' concerns – cbc.ca

Published

 on


With provinces and territories now rolling out plans to COVID-19 vaccinate children aged five to 11, many parents eagerly signed their children up to be among the first in line. 

But not everyone is pouncing on the opportunity. Some parents have more questions before their kids get the jab. 

Nathan Maharaj and his wife were up bright and early Tuesday registering their nine-year-old son for his first dose of a COVID-19 vaccine in Toronto.

  • Have a coronavirus question or news tip for CBC News? Email: Covid@cbc.ca or join us live in the comments now.

He’s excited Edmund can feel safer returning to karate classes, for instance, and will feel more comfortable planning visits to Ripley’s Aquarium, Ontario Science Centre or the movies.  

“It’s a threshold we needed to cross to do things that we were comfortable doing before and as things are opening up again,” Maharaj said. 

“We don’t want to be going there and then, you know, for the next 72 hours praying for no symptoms of anything to emerge and then also isolating from others because who knows what we’re carrying.”

Coquitlam, B.C., parent Mike Romaniuk, seen with his two young daughters Harper, centre, and Georgia, is still unsure about giving them the COVID-19 vaccine. He would like to review the studies that Canadian health officials reviewed when creating their recommendations for children. (Submitted by Mike Romaniuk)

In Coquitlam, B.C., Mike Romaniuk is digging through news sites and studies about how both COVID-19 and the vaccines for it are affecting children. While everyone in his family is up to date with B.C.’s recommended immunizations and received this season’s flu shot, he is still unsure about the COVID-19 vaccine for his daughters Harper and Georgia, who are respectively aged four and two.

“There’s definitely an aspect of ‘I don’t want to be first for my kids, I don’t want to risk,’ but I recognize on both sides there’s risk. Not doing it is a risk as well,” Romaniuk  said.

“The more data, the more confidence, I think, especially if it’s tabulated or presented in a way that’s easily understandable and comparable.”

He would love to be able see the studies Canadian health officials are analyzing to create their recommendations for children, for instance, saying that for him it would help instill more confidence. 

“There’s a lot of parents that I interact with that have concerns. They’re scared to ask [questions], scared to speak out. There’s quite a stigma around it,” he said.

The drive to vaccinate younger children against COVID-19 could prove tougher and perhaps take longer than earlier age groups, but medical experts say they’re ready to answer all questions and meet parents and caregivers where they’re at.

WATCH | Dr. Susy Hota answers viewer questions about the COVID-19 vaccine for kids: 

Why are COVID-19 vaccines necessary for kids? What about dosage for those almost 12?

2 days ago

Dr. Susy Hota, University Health Network’s medical director for infection prevention and control, answers questions about the first COVID-19 vaccine approved for Canadians aged 5-11. 7:33

Before the pandemic, the term vaccine hesitancy was most often discussed in the context of parental decision-making, according to medical anthropologist Ève Dubé, a researcher at the Quebec National Institute of Public Health who has studied it for more than a decade. 

She said before the pandemic about one-third of parents were vaccine hesitant.

“Not all those parents refused vaccines, but some were accepting with concerns, being unsure that this was the right decision,” said Dubé, who says education on the issue helps build trust and motivates parents to inoculate their children.

Looking at recent surveys, she says, there appears to be more hesitancy about COVID-19 vaccinations for the five-to-11 age group than for earlier cohorts. 

“For COVID, I think the situation is a bit different … because of the fact that children are less at risk of COVID, their direct benefit of vaccination is less clear than for measles or other childhood vaccinations,” she said.

‘A slower start’ predicted

Traditional mass public health campaigns with posters and fact sheets about the importance of vaccination typically work to reach the majority. Those positively discussing vaccines with fellow parents can also help, Dubé  said.

However, for those with many more concerns, health officials employing a targeted, one-on-one approach are most effective, she said. She admits it is more resource and time intensive.

“It might be a slower start of the [age 5-11 vaccination] campaign,” Dubé said. “But with time … the vaccine hesitancy may decrease. Most people never want to be the first in line to do something new.”   

A parent and child arrive an in-school clinic providing the Pfizer COVID-19 vaccine for children aged 5 to 11 in Wheeling, Ill., on Nov. 17. (Nam Y. Huh/Associated Press)

According to historian Catherine Carstairs, who has researched health and medicine, many people pointing to when “everyone rushed out to get the polio vaccine” forget that it actually took many years to achieve consistent uptake across different age groups. 

“I think we may see something similar with COVID-19,” said the University of Guelph history professor.

WATCH | It may take years for some to accept COVID-19 vaccines, says historian:

Why this history professor thinks COVID-19 vaccine uptake in kids could take time

7 hours ago

Catherine Carstairs, a history professor at the University of Guelph, notes how even with the polio vaccine in the 1950s, people choose to wait awhile before choosing to be immunized. 1:26

While many point to a discredited 1990s-era study falsely linking autism and vaccination for increased hesitancy of and opposition to vaccination in recent years, Carstairs believes there have also been many other contributors.

This includes more skepticism of the medical profession, the rise of “natural health” products and non-traditional medicine, a growing feminist health movement and a shift in parenting styles that puts “less reliance on outside expertise and more of a sense of ‘I know my child better than anyone,'” she said.

Working to address parent concerns

As a parent of a five-year-old himself, infectious diseases physician Alexander Wong empathizes with fellow parents who, given how fast the COVID-19 vaccines have rolled out, have more questions and simply want to do what’s best for their kids.

“We need to really kind of be open-minded and work really hard to address those concerns with parents so that we can get as many kids vaccinated as possible,” he said in Regina. 

WATCH | This infectious diseases doctor shares advice for parents with concerns:

Infectious diseases doctor and parent shares advice for fellow parents with vaccine questions

7 hours ago

Dr. Alex Wong outlines a few important points about COVID-19 vaccines for parents of younger children. 2:14

A question Wong hears regularly is that if COVID-19 has caused relatively few kids to become severely ill, hospitalized or die than adult populations, why do we need to vaccinate? 

His response: “No kid should get sick or, God forbid, die as a result of a preventable illness.… We vaccinate for things like measles, rubella, mumps, norovirus, all these other things without thinking twice. And the number of deaths caused by those types of disease conditions pre-vaccine were far, far lower than what we’re seeing with COVID.”  

More practically, he added, vaccination will minimize the intense disruptions kids and families have faced throughout the pandemic at school, with extracurricular activities and time spent with extended family and friends.

Another thing he highlights for parents is that real-world data is coming from the U.S., which approved the vaccine for children aged five to 11 in early November. Wong notes that about three million Americans kids have had one dose thus far with no major flags about side effects.

“That’s a reassuring safety signal,”  he said. “Everybody is scrutinizing this vaccine unlike anything else probably in history quite frankly.”

Leah Lefkove, 9, shows off her vaccination sticker in Decatur, Ga., on Nov. 3. It was the first day COVID-19 vaccinations were available for U.S. children from 5 to 11. (Ben Gray/The Associated Press)

Paul Offit, a professor of pediatrics and member of the Advisory Committee on Immunization Practices that authorized the COVID-19 vaccine for children in the United States, empathizes with those who feel there hasn’t been enough data gathered on this young cohort.

Yet there has never been this abundance of real-word data on teen and adult populations that can be applied to children, he told CBC Radio’s The Sunday Magazine.

Offit says contracting COVID-19 is a much riskier proposition than potential vaccine side effects. One risk of natural infection is myocarditis, or an inflammation of the heart muscle.

He said the risk of myocarditis is roughly one in 45 people who contract COVID-19, compared with roughly one in 50,000 among people who get the vaccine.

“And it’s much more severe [with infection],” Offit added.

He also pointed out that young kids who contract COVID-19 are at higher risk of a condition called Multisystem Inflammatory Syndrome in Children (MIS-C), “where myocarditis occurs 50 to 75 per cent of the time.”

LISTEN | Decision to approve COVID-19 vaccine for kids ‘nerve-wracking’ says U.S. doctor:  

The Sunday Magazine24:13Decision to approve COVID-19 vaccine for kids ‘nerve-wracking’ says American doctor

Canadian kids aged five to 11 are up next for COVID-19 shots, after Health Canada’s decision Friday to approve the Pfizer vaccine for them. Dr. Paul Offit is a member of the vaccine advisory committee that made the same recommendation in the United States earlier this month, a decision he describes as “nerve-wracking,” because he knows there’s some risk involved for young kids. But, as he writes in his new book, You Bet Your Life: From Blood Transfusions to Mass Vaccination, the Long and Risky History of Medical Innovation, all medical breakthroughs involve risk… and not getting the shot is not a risk-free choice. 24:13

In the past 200 years, any side effects associated with vaccines invariably arise within six weeks of the dose, says Offit, who is also director of the Vaccine Education Center at the Children’s Hospital of Philadelphia.

“It’s perfectly reasonable to be skeptical… You should have questions and you should have those questions answered,” he said.

“There’s a line though between that and someone who [doesn’t] trust the pharmaceutical industry, they don’t trust the medical community, they don’t trust the government and it doesn’t matter what you say, they’re simply not going to get a vaccine.

“That to me is not a vaccine skeptic. That’s a vaccine cynic.”


Have questions about this story? We’re answering as many as we can in the comments.


Adblock test (Why?)

728x90x4

Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending